[Systemic safety following intravitreal injections of anti-VEGF]. / Tolérance systémique des injections intravitréennes d'anti-VEGF.
J Fr Ophtalmol
; 41(3): 271-276, 2018 Mar.
Article
in Fr
| MEDLINE
| ID: mdl-29567019
The goal of this manuscript is to assess data suggesting that intravitreal injection of anti-vascular endothelial growth factors (anti-VEGFs) could result in systemic adverse events (AEs). The class-specific systemic AEs should be similar to those encountered in cancer trials. The most frequent AE observed in oncology, hypertension and proteinuria, should thus be the most common expected in ophthalmology, but their severity should be lower because of the much lower doses of anti-VEGFs administered intravitreally. Such AEs have not been frequently reported in ophthalmology trials. In addition, pharmacokinetic and pharmacodynamic data describing systemic diffusion of anti-VEGFs should be interpreted with caution because of significant inconsistencies reported. Thus, safety data reported in ophthalmology trials and pharmacokinetic/pharmacodynamic data provide robust evidence that systemic events after intravitreal injection are very unlikely. Additional studies are needed to explore this issue further, as much remains to be understood about local and systemic side effects of anti-VEGFs.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
Limits:
Humans
Language:
Fr
Journal:
J Fr Ophtalmol
Year:
2018
Document type:
Article
Country of publication:
France